相关实验视频

Updated: Sep 18, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

在单次注射后立即对lanreotide autogel对甲状腺瘤产生甲状腺瘤的作用

Mayuko Sumitomo, Arina Miyoshi, Shuhei Baba

Endocrinology, diabetes & metabolism case reports

|June 26, 2025

概括

一次剂量兰胺自凝液迅速使甲状腺激素水平正常化,并显著减少了患有TSH产生性垂体瘤 (TSHoma) 的患者的垂体瘤大小. 这种有效的手术前治疗有助于及时进行手术,并改善了患者的治疗结果.

科学领域:

内分泌学在内分泌学.
神经外科神经外科
在瘤学瘤学.

背景情况:

产生TSH的垂体腺瘤 (TSHomas) 导致中央甲状腺功能障碍.
手术前对TSHomas的治疗旨在使甲状腺激素水平正常化并减少瘤大小.
索马托斯坦类同类药物用于TSHomas的手术前治疗.

研究的目的:

报告一例手术前用lanreotide autogel治疗的TSHoma病例.
为了评估单剂量兰胺自凝在正常化甲状腺功能和减少瘤体积方面的疗效.
评估通过这种治疗方法促进早期手术干预的潜力.

主要方法:

一名51岁的TSHoma男性患者接受了单次皮下注射兰胺自凝 (90毫克) 的治疗.
在治疗前和治疗后进行了甲状腺功能测试 (自由T3,自由T4,TSH) 和垂体MRI.
患者在术前治疗后接受了内镜下垂体手术.

主要成果:

在lanreotide自凝剂给药4天内,自由T3和自由T4水平正常化.
在治疗7天内,垂体瘤体积减少了50%.
组织病理学检查证实了产生TSH的垂体神经内分泌瘤,手术后甲状腺激素水平正常.

结论:

单剂量兰胺自凝可以迅速使甲状腺激素水平正常化,并显著缩小TSHomas.
这种快速的治疗效果可能允许更早的外科干预,改善患者的治疗结果.
兰胺自凝是TSHomas的有效手术前治疗策略.

关键词:

产生TSH的垂体瘤兰雷化物是什么在手术前进行治疗.索马托斯塔丁的类似物

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

相关概念视频

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...